Research graph
References from Long-term real-world outcomes of nusinersen treatment in patients with spinal muscular atrophy types I–III. Local targets link to admitted publications; unresolved targets remain external evidence.
Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States
10.1186/s13023-017-0724-z · 2017 · External reference
Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy–a literature review
10.1186/s13023-017-0671-8 · 2017 · External reference
Carrier frequency of spinal muscular atrophy in Turkish population
10.2399/prn.22.0301012 · 2022 · External reference
Spinal muscular atrophy
10.1038/s41572-022-00380-8 · 2022 · External reference
Spinal muscular atrophy
10.1016/j.spen.2021.100878 · 2021 · External reference
The Children’s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability
10.1016/j.nmd.2009.11.014 · 2010 · External reference
An expanded version of the Hammersmith functional motor scale for SMA II and III patients
10.1016/j.nmd.2007.05.009 · 2007 · External reference
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
10.1016/s1474-4422(20)30037-5 · 2020 · External reference
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
10.1002/acn3.51411 · 2021 · External reference
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3
10.1136/jnnp-2020-323822 · 2020 · External reference
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
10.1186/s13023-021-02065-z · 2021 · External reference
Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
10.1186/s13023-023-02769-4 · 2023 · External reference
Effectiveness of Nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and Meta-analysis
10.1007/s40120-024-00653-2 · 2024 · External reference
Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland
10.1016/j.nmd.2022.02.001 · 2022 · External reference
Real-world data on the effect of long-term treatment with nusinersen over> 4 years in a cohort of Swiss patients with spinal muscular atrophy
10.1016/j.clineuro.2025.108983 · 2025 · External reference
Nusinersen for adults with spinal muscular atrophy
10.1007/s10072-023-06698-9 · 2023 · External reference
